LCTX

LCTX Deferred Revenue

$1.68MQuarterly · USD

Period ending:

LCTX FY Deferred RevenueUSD
LCTX FY Deferred Revenue1992-06-30: $0.001993-06-30: $0.001994-06-30: $0.001995-06-30: $0.001996-06-30: $0.001998-06-30: $0.001998-12-31: $0.001999-12-31: $0.002000-12-31: $0.002001-12-31: $0.002002-12-31: $0.002003-12-31: $407.81K2004-12-31: $901.56K2005-12-31: $140.00K2006-12-31: $183.94K2007-12-31: $261.09K2008-12-31: $312.90K2009-12-31: $367.90K2010-12-31: $550.08K2011-12-31: $465.54K2012-12-31: $400.87K2013-12-31: $235.28K2014-12-31: $208.36K2015-12-31: $2.95M2016-12-31: $572.00K2017-12-31: $797.00K2018-12-31: $42.00K2019-12-31: $45.00K2020-12-31: $193.00K2021-12-31: $18.12M2022-12-31: $9.42M2023-12-31: $10.81M2024-12-31: $7.39M2025-12-31: $3.33M$18.12M$0.00
1992-06-302025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

LCTX deferred revenue history

Revenue received but not yet earned. The available annual fiscal periods series contains 34 observations from Jun 30, 1992 to Dec 31, 2025.

Lineage Cell Therapeutics, Inc. Common Stock Deferred Revenue — Annual fiscal periods (USD)
Period endingDeferred Revenue (USD)
3,333,000
7,388,000
10,808,000
9,421,000
18,119,000
193,000
45,000
42,000
797,000
572,000
2,952,000
208,357
235,276
400,870
465,544
550,083
367,904
312,904
261,091
183,935
140,000
901,563
407,813
0
0
0
0
0
0
0
0
0
0
0

Compare deferred revenue

All LCTX financial metrics · LCTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.